GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
US8580782B2
(en)
*
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US8546082B2
(en)
*
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US20080138808A1
(en)
*
|
2003-09-11 |
2008-06-12 |
Hall Thomas A |
Methods for identification of sepsis-causing bacteria
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US8288523B2
(en)
|
2003-09-11 |
2012-10-16 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
US7767684B2
(en)
*
|
2003-11-13 |
2010-08-03 |
Abbott Laboratories |
Apoptosis promoters
|
US7973161B2
(en)
|
2003-11-13 |
2011-07-05 |
Abbott Laboratories |
Apoptosis promoters
|
US8614318B2
(en)
*
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
WO2005049593A2
(en)
*
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
EP1888550B1
(en)
*
|
2005-05-12 |
2014-06-25 |
AbbVie Bahamas Ltd. |
Apoptosis promoters
|
US8624027B2
(en)
*
|
2005-05-12 |
2014-01-07 |
Abbvie Inc. |
Combination therapy for treating cancer and diagnostic assays for use therein
|
US20080160545A1
(en)
*
|
2006-09-05 |
2008-07-03 |
Abbott Laboratories |
Pro-GRP as a surrogate marker to predict and monitor response to Bcl-2 inhibitor therapy
|
US7842681B2
(en)
|
2006-09-05 |
2010-11-30 |
Abbott Laboratories |
Treatment of myeoproliferative diseases
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
CN101535280B
(zh)
*
|
2006-11-15 |
2012-06-27 |
健泰科生物技术公司 |
芳基磺酰胺化合物
|
US20100087436A1
(en)
*
|
2006-11-16 |
2010-04-08 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
WO2008064116A2
(en)
*
|
2006-11-16 |
2008-05-29 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
WO2009011861A1
(en)
*
|
2007-07-16 |
2009-01-22 |
Poniard Pharmaceuticals, Inc. |
Oral formulations for picoplatin
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
CA2705294C
(en)
*
|
2007-11-16 |
2016-05-17 |
Abbott Laboratories |
Methods of treating arthritis by the administration of substituted benzenesulfonamides
|
MX2010006260A
(es)
*
|
2007-12-06 |
2010-08-23 |
Abbott Lab |
Composiciones orales de abt-263 para tratar cancer.
|
US20120156134A1
(en)
|
2007-12-20 |
2012-06-21 |
Shayne Squires |
Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
|
CN101220008B
(zh)
*
|
2008-01-21 |
2011-04-27 |
中国科学院广州生物医药与健康研究院 |
化合物abt-263的合成方法
|
EP2249644A4
(en)
*
|
2008-02-08 |
2012-05-30 |
Poniard Pharmaceuticals Inc |
PICOPLATIN AND AMRUBICIN USEFUL IN THE TREATMENT OF LUNG CANCER
|
ATE540026T1
(de)
*
|
2008-06-09 |
2012-01-15 |
Bristol Myers Squibb Co |
Hydroxyphenylsulfonsäureamide als antiapoptotische bcl-inhibitoren
|
US8168784B2
(en)
*
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
UA108193C2
(uk)
*
|
2008-12-04 |
2015-04-10 |
|
Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
|
US8557983B2
(en)
*
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
JP5684720B2
(ja)
*
|
2008-12-05 |
2015-03-18 |
アッヴィ・インコーポレイテッド |
癌および免疫疾患の治療のためのbcl−2−選択的アポトーシス誘発剤としてのスルホンアミド誘導体
|
US8586754B2
(en)
*
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
US8563735B2
(en)
*
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
CN102307862A
(zh)
|
2008-12-08 |
2012-01-04 |
贝林格尔.英格海姆国际有限公司 |
用于治疗癌症的化合物
|
DK2511264T3
(da)
*
|
2009-01-19 |
2015-06-22 |
Abbvie Inc |
Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme
|
KR20110116161A
(ko)
*
|
2009-01-19 |
2011-10-25 |
아보트 러보러터리즈 |
암, 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
|
US8728516B2
(en)
*
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
US8362013B2
(en)
*
|
2009-04-30 |
2013-01-29 |
Abbvie Inc. |
Salt of ABT-263 and solid-state forms thereof
|
US20100278921A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Fischer Cristina M |
Solid oral formulation of abt-263
|
US20100297194A1
(en)
*
|
2009-04-30 |
2010-11-25 |
Nathaniel Catron |
Formulation for oral administration of apoptosis promoter
|
US20100280031A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Paul David |
Lipid formulation of apoptosis promoter
|
US20220315555A1
(en)
|
2009-05-26 |
2022-10-06 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US9034875B2
(en)
|
2009-05-26 |
2015-05-19 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
RU2535347C3
(ru)
*
|
2009-05-26 |
2019-05-14 |
ЭббВи Айэленд Анлимитед Компани |
Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
|
US8546399B2
(en)
*
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
TWI471321B
(zh)
|
2009-06-08 |
2015-02-01 |
Abbott Gmbh & Co Kg |
Bcl-2族群抑制劑之口服醫藥劑型
|
TWI532484B
(zh)
*
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
SG176929A1
(en)
*
|
2009-06-18 |
2012-01-30 |
Abbott Lab |
Stable nanoparticulate drug suspension
|
SI2470166T1
(sl)
*
|
2009-08-24 |
2014-03-31 |
H.Lundbeck A/S |
Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina
|
CA2771984A1
(en)
*
|
2009-09-20 |
2011-03-24 |
Abbott Laboratories |
Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
|
EP2515883A4
(en)
*
|
2009-12-22 |
2013-07-17 |
Abbvie Inc |
CAPSULE OF ABT-263
|
US8710035B2
(en)
|
2010-03-24 |
2014-04-29 |
The University Of Chicago |
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
|
CN102947283B
(zh)
|
2010-03-25 |
2015-10-07 |
Abbvie公司 |
用于治疗癌症和免疫以及自身免疫性疾病的细胞凋亡诱导剂
|
AU2014202478B2
(en)
*
|
2010-03-25 |
2016-04-28 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
CN101798292A
(zh)
*
|
2010-03-29 |
2010-08-11 |
无锡好芳德药业有限公司 |
ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
|
TWI520960B
(zh)
|
2010-05-26 |
2016-02-11 |
艾伯維有限公司 |
用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
|
EP2575818A4
(en)
|
2010-06-03 |
2013-11-06 |
Pharmacyclics Inc |
USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
|
TWI535712B
(zh)
*
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
SG189471A1
(en)
|
2010-10-29 |
2013-05-31 |
Abbvie Inc |
Solid dispersions containing an apoptosis-inducing agent
|
DK2642999T3
(da)
*
|
2010-11-23 |
2017-01-09 |
Abbvie Ireland Unlimited Co |
Fremgangsmåder til behandling ved anvendelse af selekti-ve bcl-2-hæmmere
|
RU2628560C2
(ru)
|
2010-11-23 |
2017-08-18 |
Эббви Инк. |
Соли и кристаллические формы индуцирующего апоптоз агента
|
JP5998152B2
(ja)
*
|
2011-01-25 |
2016-09-28 |
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン |
Bcl−2/bcl−xl阻害剤およびそれを使用する治療方法
|
EP2672969A4
(en)
*
|
2011-02-01 |
2014-07-16 |
Glaxosmithkline Intellectual Property Ltd |
ASSOCIATION
|
US20140189897A1
(en)
|
2011-06-21 |
2014-07-03 |
Mayo Foundation For Medical Education And Research |
Transgenic animals capable of being induced to delete senescent cells
|
CN104039797B
(zh)
*
|
2011-10-12 |
2016-06-01 |
南京奥昭生物科技有限公司 |
作为细胞凋亡诱导剂的杂环分子
|
CN103127510B
(zh)
*
|
2011-11-30 |
2015-03-25 |
北京天和瑞通科技发展有限公司 |
含有肝细胞生长因子受体抑制剂和Bcl-2抑制剂的药物组合物及其应用
|
RU2014128010A
(ru)
|
2011-12-13 |
2016-02-10 |
Бак Инститьют Фо Рисерч Он Эйджин |
Способы улучшения средств консервативной терапии
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
WO2013158664A2
(en)
|
2012-04-17 |
2013-10-24 |
Kythera Biopharmaceuticals, Inc. |
Use of engineered viruses to specifically kill senescent cells
|
US8859774B2
(en)
|
2012-05-25 |
2014-10-14 |
Corcept Therapeutics, Inc. |
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
|
US9901080B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
|
US9901081B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse for determining the role of senescent cells in cancer
|
EP3689886A1
(en)
|
2013-01-16 |
2020-08-05 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20140279528A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Motorola Mobility Llc |
Wearable Authentication Device
|
NZ715776A
(en)
|
2013-07-30 |
2017-04-28 |
Gilead Connecticut Inc |
Polymorph of syk inhibitors
|
WO2015089402A1
(en)
|
2013-12-12 |
2015-06-18 |
The University Of Chicago |
Methods and compositions related to hsp90 inhibitors and breast cancer
|
TWI735853B
(zh)
|
2013-12-23 |
2021-08-11 |
美商克洛諾斯生技有限公司 |
脾酪胺酸激酶抑制劑
|
WO2015116735A1
(en)
|
2014-01-28 |
2015-08-06 |
Mayo Foundation For Medical Education And Research |
Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
|
SG11201606239UA
(en)
|
2014-01-28 |
2016-08-30 |
Buck Inst For Res On Aging |
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
|
CN106661039B
(zh)
|
2014-02-28 |
2019-09-13 |
林伯士拉克许米公司 |
酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
NZ726365A
(en)
|
2014-07-14 |
2018-06-29 |
Gilead Sciences Inc |
Combinations for treating cancers
|
JP6749890B2
(ja)
|
2014-08-12 |
2020-09-02 |
モナッシュ ユニバーシティ |
リンパ指向プロドラッグ
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
WO2016131100A1
(en)
*
|
2015-02-18 |
2016-08-25 |
The Walter And Eliza Hall Institute Of Medical Research |
Methods of treating infectious diseases
|
TWI744225B
(zh)
|
2015-02-27 |
2021-11-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
US10195213B2
(en)
|
2015-03-13 |
2019-02-05 |
Unity Biotechnology, Inc. |
Chemical entities that kill senescent cells for use in treating age-related disease
|
ES2965461T3
(es)
|
2015-08-03 |
2024-04-15 |
Biokine Therapeutics Ltd |
Inhibidor de CXCR4 para el tratamiento del cáncer
|
TWI707852B
(zh)
|
2015-09-02 |
2020-10-21 |
美商林伯士拉克許米公司 |
Tyk2 抑制劑及其用途
|
CN114031658A
(zh)
|
2015-09-08 |
2022-02-11 |
莫纳什大学 |
定向淋巴的前药
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
EP3364958B1
(en)
|
2015-10-23 |
2023-01-04 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
WO2017101851A1
(en)
*
|
2015-12-18 |
2017-06-22 |
Unity Biotechnology, Inc. |
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
|
MA43870A
(fr)
|
2016-01-11 |
2021-05-26 |
Celator Pharmaceuticals Inc |
Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr)
|
JP2019501225A
(ja)
*
|
2016-01-11 |
2019-01-17 |
メリマック ファーマシューティカルズ インコーポレーティッド |
B細胞リンパ腫2(bcl−2)及び関連タンパク質の阻害
|
US11014882B2
(en)
*
|
2016-03-09 |
2021-05-25 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
LT3426243T
(lt)
|
2016-03-09 |
2021-08-10 |
Raze Therapeutics, Inc. |
3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas
|
WO2017157825A1
(en)
|
2016-03-15 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
KR102511028B1
(ko)
|
2016-03-15 |
2023-03-16 |
오리존 지노믹스 에스.에이. |
혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
|
KR102275758B1
(ko)
|
2016-03-28 |
2021-07-12 |
프레시지 바이오싸이언시스, 인크. |
암 치료를 위한 제약학적 조합물
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
CN109152933B
(zh)
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
JP7084624B2
(ja)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
CA3027498A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
CA3040286A1
(en)
|
2016-10-21 |
2018-04-26 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
WO2018085069A1
(en)
|
2016-11-03 |
2018-05-11 |
Gilead Sciences, Inc. |
Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
WO2018106636A1
(en)
|
2016-12-05 |
2018-06-14 |
Raze Therapeutics, Inc. |
Shmt inhibitors and uses thereof
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
EP3592746B1
(en)
|
2017-03-08 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
SG11201908790PA
(en)
|
2017-03-31 |
2019-10-30 |
Corcept Therapeutics Inc |
Glucocorticoid receptor modulators to treat cervical cancer
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
AU2018258355B2
(en)
|
2017-04-26 |
2024-05-30 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
AU2018306444B2
(en)
|
2017-07-28 |
2022-11-17 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
ES2926195T3
(es)
|
2017-08-04 |
2022-10-24 |
Bicycletx Ltd |
Ligandos peptídicos bicíclicos específicos de CD137
|
CA3073871A1
(en)
|
2017-08-25 |
2019-02-28 |
Gilead Sciences, Inc. |
Polymorphs of syk inhibitors
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
BR112020012997A2
(pt)
|
2017-12-26 |
2020-12-01 |
Kymera Therapeutics, Inc. |
degradadores de irak e usos dos mesmos
|
CN111788203A
(zh)
|
2018-01-10 |
2020-10-16 |
里科瑞尔姆Ip控股有限责任公司 |
苯甲酰胺化合物
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
AU2019211485A1
(en)
|
2018-01-29 |
2020-08-06 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
CA3089769A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
KR20200140262A
(ko)
|
2018-02-27 |
2020-12-15 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
WO2019178433A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
|
HUE058746T2
(hu)
|
2018-04-24 |
2022-09-28 |
Merck Patent Gmbh |
Antiproliferációs vegyületek és felhasználásuk
|
AR114828A1
(es)
|
2018-04-24 |
2020-10-21 |
Vertex Pharma |
Compuestos de pteridinona y sus usos
|
CA3098348A1
(en)
|
2018-04-29 |
2019-11-07 |
Beigene, Ltd. |
Bcl-2 inhibitors
|
IL314362A
(en)
|
2018-06-15 |
2024-09-01 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and their uses
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
WO2020024976A1
(en)
|
2018-07-31 |
2020-02-06 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
|
US11491168B2
(en)
|
2018-07-31 |
2022-11-08 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
CN113164419A
(zh)
|
2018-09-07 |
2021-07-23 |
皮克医疗公司 |
Eif4e抑制剂和其用途
|
SG11202101955SA
(en)
*
|
2018-09-18 |
2021-03-30 |
Signalchem Lifesciences Corp |
Combination therapy for treating blood cancer
|
EP3866789A4
(en)
|
2018-10-15 |
2022-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
CN113164414A
(zh)
|
2018-10-24 |
2021-07-23 |
纳维托制药有限公司 |
多晶型化合物和其用途
|
BR112021010484A2
(pt)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics, Inc. |
Degradadores de irak e usos dos mesmos
|
JP7530360B2
(ja)
|
2018-11-30 |
2024-08-07 |
武田薬品工業株式会社 |
Tyk2阻害剤およびその使用
|
US11389432B2
(en)
|
2018-12-19 |
2022-07-19 |
Corcept Therapeutics Incorporated |
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
|
US11234971B2
(en)
|
2018-12-19 |
2022-02-01 |
Corcept Therapeutics Incorporated |
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
|
EP3897589A4
(en)
|
2018-12-19 |
2022-10-12 |
Corcept Therapeutics Incorporated |
PHARMACEUTICAL FORMULATIONS CONTAINING A RELACORILANT, AN AZADECALIN COMPOUND FUSED WITH A HETEROARYL KETONE
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3914357A4
(en)
|
2019-01-23 |
2022-10-12 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND THEIR USES
|
CN113490496A
(zh)
|
2019-02-22 |
2021-10-08 |
科赛普特治疗学股份有限公司 |
一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
|
WO2020172431A1
(en)
|
2019-02-22 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of condensed pyrazines as syk inhibitors
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
AU2020253633A1
(en)
|
2019-04-05 |
2021-11-04 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
AU2020293230A1
(en)
|
2019-06-12 |
2022-01-27 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
|
AU2020345962A1
(en)
|
2019-09-11 |
2022-03-31 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
AU2020347274A1
(en)
|
2019-09-13 |
2022-03-31 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
IL292612A
(en)
|
2019-11-01 |
2022-07-01 |
Navitor Pharm Inc |
Treatment methods using mtorc1 modulator
|
KR20220098755A
(ko)
|
2019-11-05 |
2022-07-12 |
애브비 인코포레이티드 |
나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
MX2022007576A
(es)
|
2019-12-17 |
2022-09-23 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
CA3162502A1
(en)
|
2019-12-23 |
2021-07-01 |
Yi Zhang |
Smarca degraders and uses thereof
|
AU2021217172A1
(en)
|
2020-02-05 |
2022-09-22 |
Monash University |
Lipid prodrugs of neurosteroids
|
CN115515685A
(zh)
|
2020-03-03 |
2022-12-23 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
KR20230005160A
(ko)
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
US20230270816A1
(en)
|
2020-07-06 |
2023-08-31 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
JP2023536462A
(ja)
|
2020-07-30 |
2023-08-25 |
カイメラ セラピューティクス, インコーポレイテッド |
変異体リンパ腫を処置する方法
|
MX2023001588A
(es)
|
2020-08-17 |
2023-05-03 |
Bicycletx Ltd |
Conjugados biciclo específicos para nectina-4 y usos de estos.
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
US20230113202A1
(en)
|
2021-02-02 |
2023-04-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
CA3207380A1
(en)
|
2021-02-15 |
2022-08-18 |
Haojing RONG |
Irak4 degraders and uses thereof
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
US12071442B2
(en)
|
2021-03-29 |
2024-08-27 |
Nimbus Saturn, Inc. |
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230150997A1
(en)
|
2021-08-25 |
2023-05-18 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
GB202201824D0
(en)
|
2022-02-11 |
2022-03-30 |
Genome Res Ltd |
Methods of treatment
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023215449A1
(en)
|
2022-05-06 |
2023-11-09 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
WO2023215471A1
(en)
|
2022-05-06 |
2023-11-09 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
US20240238423A9
(en)
|
2022-05-06 |
2024-07-18 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2024012557A1
(en)
*
|
2022-07-15 |
2024-01-18 |
Berrybio (Hong Kong) Limited |
Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
|
TW202416950A
(zh)
|
2022-08-02 |
2024-05-01 |
英商利米那生物科技有限公司 |
雜芳基甲醯胺及相關gpr84拮抗劑及其用途
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
TW202416972A
(zh)
|
2022-08-02 |
2024-05-01 |
英商利米那生物科技有限公司 |
經取代之吡啶酮gpr84拮抗劑及其用途
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2024184233A1
(en)
|
2023-03-03 |
2024-09-12 |
Ionctura Sa |
Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy
|